TCF4 and nasopharyngeal carcinoma: PTPRG-AS1 promotes radioresistance in two cancer types: in nasopharyngeal carcinoma (NPC), PTPRG-AS1 reduces sensitivity to radiotherapy through the miR-194-3p/PRC1 regulatory axis [103]; whereas, under X-ray irradiation, overexpression of PTPRG-AS1 could promote the viability and enhance the radioresistance of NSCLS by modulating the miR-200c-3p/TCF4 axis [104].